On August 2, 2022 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, reported that the U.S. Patent and Trademark Office (USPTO) has granted the patent (Patent No. US 11,401,329) of its anti-CD47 antibodies (Press release, Phanes Therapeutics, AUG 2, 2022, View Source [SID1234617318]). The patent relates to the invention of anti-CD47 monoclonal antibodies and bispecific antibodies comprising an anti-CD47 arm, including PT886, an anti-claudin18.2/anti-CD47 bispecific antibody being developed for gastric and pancreatic cancers, and PT217, an anti-DLL3/anti-CD47 bispecific antibody being developed for the treatment of small cell lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Phanes has received clearance from the US FDA to commence Phase I studies with PT886 in June 2022 and expect to file IND with PT217 this year. Both PT886 and PT217 have been granted orphan drug designation from the FDA in June this year.

"This is the sixth Phanes patent granted this year." said Dr. Ming Wang, PhD, MBA, Founder and CEO of Phanes Therapeutics. "As Phanes expands from a research to a clinical development stage organization, we expect to have additional patent applications issued, further strengthening the intellectual property portfolio and competitiveness of our pipeline."